Login to Your Account

Regulatory NEWS

The Senate committee on Health, Education, Labor and Pensions (HELP) voted the FDA Device Accountability Act of 2015 (S. 1622), along with six other health care-related bills, out of committee at a Feb. 9 executive session. Bipartisan comity was on display for most of the hearing, although one piece of legislation seems destined to stir up yet more controversy on Capitol Hill.

The FDA's plan to get tough on opioid abuse is a good first step, but it isn't enough to get two Democrat senators to lift their holds on Robert Califf's nomination as the next FDA commissioner.

FDA briefing documents released Friday morning in advance of Tuesday's Arthritis Advisory Committee Meeting (adcom) suggested the agency will go gentle on the biologics license application for CT-P13, Celltrion Inc.'s biosimilar to Remicade (infliximab, Janssen Biotech Inc.) that is approved elsewhere as Remsima (infliximab).

More Regulatory Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: